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IMPORTANCE InDecember 2019, a novel coronavirus (severe acute respiratory syndromecoro-
navirus 2 [SARS-CoV-2]) emerged inChina andhas spreadglobally, creating apandemic. Informa-
tion about the clinical characteristics of infectedpatientswho require intensive care is limited.
OBJECTIVE To characterize patients with coronavirus disease 2019 (COVID-19) requiring
treatment in an intensive care unit (ICU) in the Lombardy region of Italy.
DESIGN, SETTING, AND PARTICIPANTS Retrospective case series of 1591 consecutive patients
with laboratory-confirmed COVID-19 referred for ICU admission to the coordinator center
(Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy) of the COVID-19
Lombardy ICU Network and treated at one of the ICUs of the 72 hospitals in this network
between February 20 andMarch 18, 2020. Date of final follow-up wasMarch 25, 2020.
EXPOSURES SARS-CoV-2 infection confirmed by real-time reverse transcriptase–polymerase
chain reaction (RT-PCR) assay of nasal and pharyngeal swabs.
MAIN OUTCOMES ANDMEASURES Demographic and clinical data were collected, including
data on clinical management, respiratory failure, and patient mortality. Data were recorded
by the coordinator center on an electronic worksheet during telephone calls by the staff of
the COVID-19 Lombardy ICU Network.
RESULTS Of the 1591 patients included in the study, themedian (IQR) age was 63 (56-70)
years and 1304 (82%) weremale. Of the 1043 patients with available data, 709 (68%) had at
least 1 comorbidity and 509 (49%) had hypertension. Among 1300 patients with available
respiratory support data, 1287 (99% [95% CI, 98%-99%]) needed respiratory support,
including 1150 (88% [95% CI, 87%-90%]) who receivedmechanical ventilation and
137 (11% [95% CI, 9%-12%]) who received noninvasive ventilation. Themedian positive
end-expiratory pressure (PEEP) was 14 (IQR, 12-16) cmH2O, and FIO2 was greater than 50% in
89% of patients. Themedian PaO2/FIO2 was 160 (IQR, 114-220). Themedian PEEP level was
not different between younger patients (n = 503 aged63 years) and older patients (n = 514
aged64 years) (14 [IQR, 12-15] vs 14 [IQR, 12-16] cmH2O, respectively; median difference,
0 [95% CI, 0-0]; P = .94). Median FIO2 was lower in younger patients: 60% (IQR, 50%-80%)
vs 70% (IQR, 50%-80%) (median difference, −10% [95% CI, −14% to 6%]; P = .006), and
median PaO2/FIO2 was higher in younger patients: 163.5 (IQR, 120-230) vs 156 (IQR, 110-205)
(median difference, 7 [95% CI, −8 to 22]; P = .02). Patients with hypertension (n = 509) were
older than those without hypertension (n = 526) (median [IQR] age, 66 years [60-72] vs 62
years [54-68]; P < .001) and had lower PaO2/FIO2 (median [IQR], 146 [105-214] vs 173
[120-222]; median difference, −27 [95% CI, −42 to −12]; P = .005). Among the 1581 patients
with ICU disposition data available as of March 25, 2020, 920 patients (58% [95% CI,
56%-61%]) were still in the ICU, 256 (16% [95% CI, 14%-18%]) were discharged from the ICU,
and 405 (26% [95% CI, 23%-28%]) had died in the ICU. Older patients (n = 786; age64
years) had higher mortality than younger patients (n = 795; age63 years) (36% vs 15%;
difference, 21% [95% CI, 17%-26%]; P < .001).
CONCLUSIONS AND RELEVANCE In this case series of critically ill patients with
laboratory-confirmed COVID-19 admitted to ICUs in Lombardy, Italy, the majority were older
men, a large proportion requiredmechanical ventilation and high levels of PEEP, and ICU
mortality was 26%.
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O nMarch11,2020,theWorldHealthOrganization(WHO)declared the severe acute respiratory syndrome coro-navirus2(SARS-CoV-2)outbreakapandemicduetothe
constantly increasing number of cases outside China.1 Pa-
tientswith SARS-CoV-2 infection candevelop coronavirusdis-
ease 2019 (COVID-19), which has resulted in high rates of hos-
pitalization and intensive care unit (ICU) admission.2
On February 20, 2020, the first patient diagnosed with
COVID-19 in Italy developed respiratory failure and was
admitted to one of the ICUs of Lombardy, a region of north-
ern Italy. Since then, the increasing number of cases recorded
in Lombardy, and subsequently throughout the country, led
Italy to be the second most affected country in the world,
after the US, as of March 27, 2020.3 Local health and govern-
ment officials in Lombardy responded to the outbreak by cre-
ating a network of ICUs (COVID-19 Lombardy ICU Network)
coordinated by Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico, Milan. This network has managed an
exponential surge of patients requiring ICU admission for
respiratory support.2
Up through March 18, 2020, a total of 17 713 people
had tested positive for the new SARS-CoV-2 coronavirus in
Lombardy and 1593 (9%) had been admitted to the ICU.
Information on the incidence and clinical characteristics of
critically ill patients diagnosed with COVID-19 is still lim-
ited. Among hospitalized patients with COVID-19 in China,
the percentage of patients who required ICU care has varied
from 5% to 32%.4,5
The availability of ICU beds and the provision of inten-
sive care varies among countries.6 Knowledge of the baseline
characteristics and outcomes of critically ill patients is cru-
cial for health and government officials engaged in planning
efforts to address local outbreaks. This case series describes
the clinical characteristics of patients with laboratory-
confirmed COVID-19 admitted to ICUs of the COVID-19 Lom-
bardy ICU Network in northern Italy.
Methods
This retrospective observational study was performed at the
Fondazione IRCCSCa’ GrandaOspedaleMaggiore Policlinico,
Milan, which was the regional coordinating center for the
COVID-19 Lombardy ICU Network. All consecutive patients
with laboratory-confirmed SARS-CoV-2 infection, referred to
OspedaleMaggiore Policlinico, and subsequently admitted to
one of the ICUs among 72 hospitals in the network between
February 20 and March 18, 2020, were enrolled. The institu-
tional ethics board of Fondazione IRCCSCa’ GrandaOspedale
Maggiore Policlinico, Milan, approved this study and due to
the nature of retrospective chart review, waived the need for
informed consent from individual patients.
According to the WHO guidance,7 laboratory confirma-
tion for SARS-Cov-2 was defined as a positive result of real-
time reverse transcriptase–polymerase chain reaction (RT-
PCR) assay of nasal and pharyngeal swabs. This guidancewas
implemented locally with the adjunct of using RT-PCR assay
from lower respiratory tract aspirates as well.
Data were recorded by staff of the coordinator center on
an electronic worksheet during daily telephone calls per-
formed by intensivists of the hospitals of the COVID-19
Lombardy ICU Network.
Data Collection
Clinical data reported in this study were collected by phone
within the first 6 to 24hours following ICUadmission. The re-
corded data included the following: age, sex,medical comor-
bidities,modeof respiratorysupport (invasivemechanicalven-
tilation, noninvasive mechanical ventilation, oxygen mask),
level ofpositiveend-expiratorypressure (PEEP), fractionof in-
spiredoxygen (FIO2), arterial partial pressureof oxygen (PaO2),
PaO2/FIO2 ratio, the use of extracorporeal membrane oxygen-
ation (ECMO), andprone positioning. Thenumber of patients
who had died, had been discharged, and were still admitted
in the ICUasofMarch25, 2020,were recorded, and ICU length
of stay also was determined.
Statistical Analysis
No statistical sample size calculation was performed a priori,
and sample size was equal to the number of patients treated
during the study period. Continuous variables are presented
as median and interquartile range (IQR) with 95% CIs.
Categorical variables areexpressedasnumberofpatients (per-
centage) with 95% CIs. Differences in distributions of patient
characteristics by median age subgroups and by presence/
absence of hypertension are reported using differences with
95% CIs. Percentages of available data for the overall popula-
tion are based on the total number of patients included in the
study,distributionof availabledataover theage subgroupsare
basedon theavailabledata for that variable, and theotherper-
centages are calculatedusing thenumber of available data for
that subgroup.
Patients were grouped by age and by median age. Age
groupsweredefinedas follows:0 through20years; 21 through
40years; 41 through50years; 51 through60years; 61 through
70 years; 71 through 80 years; 81 through 90 years; and 91
through 100 years. Younger and older age were classified as
age lower than the median age and age equal or higher than
the median age.
Key Points
Question What are the baseline characteristics and outcomes of
patients with laboratory-confirmed severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection admitted to
intensive care units (ICUs) in Lombardy, Italy?
Findings In this retrospective case series that involved 1591
critically ill patients admitted from February 20 toMarch 18, 2020,
99% (1287 of 1300 patients) required respiratory support,
including endotracheal intubation in 88% and noninvasive
ventilation in 11%; ICUmortality was 26%.
Meaning In this case series of critically ill patients admitted to
ICUs in Lombardy, Italy, with laboratory-confirmed coronavirus
disease 2019 (COVID-19), a high proportion requiredmechanical
ventilation and ICUmortality was 26% as of March 25, 2020.
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Mann-Whitney rank sum test was used to compare non-
parametric continuous variables between median age sub-
groupsandpatientswithorwithouthypertension. χ2orFisher
exact testwasused for categorical variables as appropriate.All
statistical tests were 2-tailed, and statistical significance was
definedasP < .05.AnalyseswereperformedusingSAS9.4.The
analyseshavenotbeenadjusted formultiple comparisons, and
given the possibility of type I error, the findings should be in-
terpreted as exploratory and descriptive.
Results
From February 20 to March 18, 2020, a total of 1694 patients
with suspectedor confirmedCOVID-19were referred to theco-
ordinating center. A total of 77 patients had pending and 24
patients had negative test results for SARS-CoV-2; for 2 pa-
tients, datawere not available. Thus, data from 1591 critically
ill patients with laboratory-confirmed COVID-19 were in-
cluded in this report.
Table 1 shows the demographic and clinical characteris-
tics of the patients. Overall, 82% (1304 of 1591 patients [95%
CI, 79.98%-83.82%]) were male, similarly distributed
among all age groups. The median age was 63 years (IQR,
56-70) (range, 14-91 years [95% CI, 63-64]) among 1591
patients. A total of 363 patients (23% [95% CI, 21%-25%])
were aged 71 years and older, and 203 (13% [95% CI, 11%-
15%]) were younger than 51 years. In this report, median age
was used to stratify patients as younger (age ≤63 years) or
older (age ≥64 years).
Table 1. Demographic and Clinical Characteristics of Patients in the First 24 Hours of ICU Admission for COVID-19 in Lombardy, Italy
Patients by age, y, No. (%)
All 0-20 21-40 41-50 51-60 61-70 71-80 81-90 91-100
No. (%) 1591 (100) 4 (<1) 56 (4) 143 (9) 427 (27) 598 (38) 341 (21) 21 (1) 1 (<1)
Age, median (IQR), y 63 (56-70) 16
(14-19)
34
(31-38)
47
(44-49)
56
(54-59)
65
(63-68)
74
(72-76)
83
(81-84)
91
Males 1304 (82) 3 (75) 44 (79) 119 (83) 355 (83) 484 (81) 279 (82) 19 (90) 1 (100)
Females 287 (18) 1 (25) 12 (21) 24 (17) 72 (17) 114 (19) 62 (18) 2 (10) 0
Comorbidities,
No. with data
1043 3 35 82 273 380 253 1 1
None 334 (32) 0 23 (66) 50 (61) 107 (39) 107 (28) 47 (19) 0 0
Hypertension 509 (49) 0 4 (11) 21 (26) 121 (44) 195 (51) 156 (62) 12 (75) 0
Cardiovascular diseasea 223 (21) 0 1 (3) 4 (5) 43 (16) 87 (23) 81 (32) 6 (38) 1 (100)
Hypercholesterolemia 188 (18) 0 1 (3) 1 (1) 30 (11) 92 (24) 59 (23) 5 (31) 0
Diabetes, type 2 180 (17) 0 1 (3) 4 (5) 40 (15) 86 (23) 46 (18) 3 (19) 0
Malignancyb 81 (8) 0 0 2 (2) 10 (4) 33 (9) 33 (13) 3 (19) 0
COPD 42 (4) 0 1 (3) 0 8 (3) 12 (3) 20 (8) 1 (6) 0
Chronic kidney disease 36 (3) 0 0 2 (2) 10 (4) 17 (4) 7 (3) 0 0
Chronic liver disease 28 (3) 0 0 2 (2) 8 (3) 13 (3) 5 (2) 0 0
Otherc 205 (20) 3 (100) 6 (17) 10 (12) 49 (18) 77 (20) 55 (22) 5 (31) 0
Respiratory support, No. 1300 2 46 108 351 487 287 18 1
Invasive mechanical
ventilation
1150 (88) 2 (100) 37 (80) 87 (81) 315 (90) 449 (92) 246 (86) 14 (78) 0
Noninvasive ventilation 137 (11) 0 8 (17) 16 (15) 33 (9) 36 (7) 39 (14) 4 (22) 1 (100)
Oxygen mask 13 (1) 0 1 (2) 5 (5) 3 (1) 2 (<1) 2 (1) 0 0
PEEP, cm H2O
No. 1017 2 33 81 278 377 234 11 1
Median (IQR) 14 (12-16) 9.5
(5-14)
14
(10-15)
14
(12-15)
14
(12-15)
14
(12-16)
14
(12-15)
12
(8-15)
10
FIO2, %
No. 999 2 31 81 270 375 228 11 1
Median (IQR) 70 (50-80) 40
(30-50)
60
(50-70)
60
(50-80)
65
(50-80)
70
(55-80)
70
(50-80)
60
(50-90)
60
PaO2/FIO2 ratio
No. 781 2 26 58 213 306 169 7 0
Median (IQR) 160
(114-220)
259
(195-323)
201.5
(123-248)
168.5
(112-260)
163
(120-230)
152.5
(110-213)
163
(120-205)
150
(86-250)
NA
Prone position,
No./total (%)
240/875 (27) 0/2 3/25 (12) 24/71 (34) 70/247 (28) 90/337 (27) 51/187 (27) 2/6 (33) NA
ECMO, No./total (%) 5/498 (1) NA 0/15 0/42 2/149 (1) 3/193 (2) 0/95 0/4 NA
Abbreviations: COPD, chronic obstructive pulmonary disease; ECMO,
extracorporeal membrane oxygenation; FIO2, Fraction of inspired oxygen; ICU,
intensive care unit; IQR, interquartile range; NA, not applicable; PaO2, arterial
partial pressure of oxygen; PEEP, positive end-expiratory pressure.
a Cardiovascular disease includes cardiomyopathy and heart failure.
bMalignancy includes active neoplasia and neoplasia in remission.
c Other includes anemia, asthma, inflammatory bowel disease, epilepsy, chronic
respiratory insufficiency, endocrine disorders, connective tissue diseases,
neurologic disorders, chronic pancreatitis, immunocompromise, and organ
transplant.
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Sixty-eight percent (95% CI, 65%-71%) of patients had at
least 1 comorbidity. Hypertension was the most common co-
morbidity, affecting 509 (49%[95%CI, 46%-52%]) of 1043pa-
tients with available data. The secondmost common comor-
bidities were cardiovascular disease (223 patients, 21% [95%
CI, 19%-24%]) and hypercholesterolemia (188 patients, 18%
[95% CI, 16%-20%]). Only 42 patients (4% [95% CI, 3%-5%])
hadahistoryof chronicobstructivepulmonarydisease.All the
patientsolder than80yearshadat least 1 comorbidity, and496
of 650 patients (76% [95%CI, 73%-80%]) older than 60 years
had at least 1 comorbidity.
Among 1300 patients with available respiratory support
data, 1287 (99%[95%CI,98%-99%])whowereadmitted to the
ICUneeded invasiveornoninvasive respiratorysupport.A total
of 1150 patients (88% [95% CI, 87%-90%]) required endotra-
cheal intubation and mechanical ventilation, and 137 pa-
tients (11% [95% CI, 9%-12%]) were treated with noninvasive
ventilation. Invasive mechanical ventilation was used in 565
(88% [95% CI, 85%-90%]) of the 645 younger patients with
available data and in 585 (89% [95%CI, 87%-92%]) of the 655
older patients (difference, −2% [95% CI, −5% to 2%]; P = .33).
Noninvasive ventilation was used in 70 (11% [95% CI, 9%-
14%]) of the 645 younger patients with available data and in
67 (10% [95% CI, 8%-13%]) of the 655 older patients (differ-
ence, −1% [95% CI, −4% to 3%]; P = .71).
The median (IQR) positive end-expiratory pressure
(PEEP) was 14 (12-16) cm H2O (n = 1017). PEEP levels as high
as 22 cm H2O were applied. Among a total of 999 patients
with available data, 887 (89% [95% CI, 87%-91%]) required a
fraction of inspired oxygen (FIO2) of at least 50%, and 120
(12% [95% CI, 10%-14%]) required 100% FIO2. The median
PaO2/FIO2 ratio was 160 (IQR, 114-220 [95% CI, 152-166])
(n = 781). PEEP level grouped by median age was not signifi-
cantly different (median, 14 [IQR, 12-15] cm H2O in the group
aged ≤63 years vs 14 cm H2O [IQR, 12-16] in the group aged
≥64 years; median difference, 0 [95% CI, 0-0]; P = .94). FIO2
was higher in older patients (median, 60% [IQR, 50%-80%]
in the group aged ≤63 years vs 70% [IQR, 50%-80%] in the
group aged ≥64 years; median difference, −10% [95% CI,
−14% to −6%]; P = .006). PaO2/FIO2 was higher in the younger
patients (163.5 [IQR, 120-230] in the group aged ≤63 years vs
156 [IQR, 110-205] in the group aged ≥64 years; median dif-
ference, 7 [95% CI, −8 to 22]; P = .02).
The Figure shows distribution of age, PEEP, FIO2, and
PaO2/FIO2. At admission, 240 of 875 patients (27% [95% CI,
25%-31%]) were treated with prone ventilation and 5 of 498
Figure. Distribution of Age and RespiratoryMeasures on Admission to a COVID-19 Intensive Care Unit
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COVID-19 indicates coronavirus disease 2019; PEEP, positive end-expiratory pressure; FIO2, fraction of inspired oxygen; PaO2, arterial partial pressure of oxygen.
Boxplots show the 25th, 50th, and 75th percentiles (box); 10th and 90th percentiles (whiskers); and outlying points (circles).
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(1% [95% CI, 0.3%-2%]) required extracorporeal membrane
oxygenation (ECMO).
Compared with patients without hypertension (n = 526),
patients with hypertension (n = 509) were significantly older
(median age, 66 [IQR, 60-72] years vs 62 [IQR, 54-68] years;
median difference, 4 [95% CI, 2-6]; P < .001) and had higher
PEEP levels (median [IQR], 14 [12-16] vs 14 [12-15] cm H2O;
median difference, 0 [95% CI, 0-0]; P = .003) and lower PaO2/
FIO2 (median, 146 [IQR, 105-214] vs 173 [IQR, 120-222];
median difference, −27 [95% CI, −42 to −12; P = .005). How-
ever, there was no statistically significant difference in FIO2
(median, 70 [IQR, 50-80] in the group with hypertension vs
60 [IQR, 50-80] in the group without hypertension; median
difference, 10 [95% CI, 6-14]; P = .05).
Among the 1581 patients with ICU disposition data avail-
able as of March 25, 2020, 920 patients (58% [95% CI, 56%-
61%]) were still in the ICU, 256 (16% [95% CI, 14%-18%]) had
been discharged from the ICU, and 405 (26% [95% CI, 23%-
28%]) had died in the ICU. ICU mortality was higher in those
whowereolder (Table2). ICUmortalitywas significantly lower
in younger patients (≤63 years) comparedwith older patients
(≥64 years) (15% vs 36%; difference, −21% [95% CI, −26% to
−17%]; P < .001). The percentage of patients discharged from
the ICUwas significantlyhigher amongyoungerpatients com-
paredwitholder patients (21%vs 11%; difference, 9% [95%CI,
6%-13%]; P < .001).
As of March 25, 2020, the median (IQR) length of stay in
the ICU was 9 (6-13 [95% CI, 9-9]) days (n = 1591). Among
patients still in the ICU (n = 920), the median (IQR) length of
stay was 10 days (8-14 [95% CI, 10-11]); among patients dis-
charged from the ICU (n = 256), the median length of stay
was 8 days (5-12 [95% CI, 8-9]); and among patients who died
in the ICU (n = 405), the median length of stay was 7 (5-11
[95% CI, 7-8]) days.
The prevalence of hypertension was higher among
patients who died in the ICU (63%, 195 of 309 patients)
compared with those discharged from the ICU (40%, 84 of
212 patients) (difference, 23% [95% CI, 15%-32%]; P < .001)
(Table 2).
Discussion
In this case series of critically ill patients admitted to ICUs in
Lombardy, Italy, with laboratory-confirmed COVID-19 from
February 20 toMarch 18, 2020, themajority were oldermen,
a large proportion required mechanical ventilation and high
levels of PEEP, and ICUmortality was 26%.
The majority of patients in this case series were admitted
to the ICU because of acute hypoxemic respiratory failure
that required respiratory support. Endotracheal intubation
and invasive mechanical ventilation were needed in 88% of
the patients, whereas only 11% could be managed with non-
invasive ventilation. The need for invasive mechanical venti-
lation in this patient population was higher than that recently
reported for other ICU patients: 71% (Washington State, US),8
47% (Wuhan, China),9 42% (Wuhan, China)10 and 30% (Wu-
han, China; of note, half of these were treated with ECMO).5
The need for invasive mechanical ventilation in this critically
ill Italian patient population was also higher compared with
data reported by 2 Chinese studies fromWuhan, including all
adult inpatients with laboratory-confirmed COVID-19 and
patients hospitalized with severe disease (with rates of 17%11
and 15%,4 respectively).
Table 2. Patient Disposition FromCOVID-Only Intensive Care Units (ICUs), Total and Stratified by History of Hypertension
Patients by age, y, No. (%)
All
(N = 1591)
0-20
(n = 4)
21-40
(n = 56)
41-50
(n = 143)
51-60
(n = 427)
61-70
(n = 598)
71-80
(n = 341)
81-90
(n = 21)
91-100
(n = 1)
Overall
Outcome, No. with data 1581 2 56 142 423 596 340 21 1
Died in ICU 405 (26) 0 4 (7) 16 (11) 63 (15) 174 (29) 136 (40) 11 (52) 1 (100)
Discharged from ICU 256 (16) 0 20 (36) 35 (25) 90 (21) 69 (12) 40 (12) 2 (10) 0
Still in ICU as of 3/25/2020a 920 (58) 2 (100) 32 (57) 91 (64) 270 (64) 353 (59) 164 (48) 8 (38) 0
Patients with hypertensionb
No. 509 0 4 (<1) 21 (4) 121 (24) 195 (38) 156 (31) 12 (2) 0
Outcome
Died in ICU 195 (38) 0 0 4 (19) 24 (20) 82 (42) 78 (50) 7 (58) 0
Discharged from ICU 84 (16) 0 1 (25) 8 (38) 26 (21) 25 (13) 23 (15) 1 (8) 0
Still in ICU as of 3/25/2020a 230 (58) 0 3 (75) 9 (43) 71 (59) 88 (45) 55 (35) 4 (33) 0
Patients without hypertensionb
No. 526 1 (<1) 31 (6) 60 (11) 148 (28) 184 (35) 97 (18) 4 (1) 1 (<1)
Outcome
Died in ICU 114 (22) 0 3 (10) 3 (5) 21 (14) 43 (23) 40 (41) 3 (75) 1 (100)
Discharged from ICU 128 (24) 0 17 (55) 19 (32) 47 (32) 33 (18) 12 (12) 0 0
Still in ICU as of 3/25/2020a 284 (54) 1 (100) 11 (35) 38 (63) 80 (54) 108 (59) 45 (46) 1 (25) 0
a Patients were admitted between 2/20/2020 and 3/18/2020, with follow-up
through 3/25/2020.
bHypertension status for those with outcome data was available for 1035
patients; hypertension status overall was available for 1043 patients.
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Conversely, in previously cited reports, noninvasive ven-
tilation has been used much more frequently both inside and
outside the ICU. For the ICU population, the use of noninva-
sive ventilation was reported as 19% (Washington State, US),8
42% (Wuhan, China),9 56% (Wuhan, China),10 and 62%
(Wuhan, China; of note, this value included patients receiv-
ing high-flow nasal cannula).5 In previous reports, noninva-
sive ventilation was used in 14% of adult inpatients with
laboratory-confirmed COVID-1911 and 32% of hospitalized
patients with severe laboratory-confirmed COVID-19.4
The higher rate of intubation in the current case series
could be due to the severity of hypoxia (themedian PaO2/FIO2
was 160), thus requiring high levels of PEEP. However, in one
of the recent reports, the PaO2/FIO2 ratio upon ICU admission
was even lower (136).9 Another potential explanation is that
themajority of the patients requiring noninvasive ventilation
innorthern Italywere able to bemanagedoutside the ICUand
were thusnot included in this report. Data regardinguseof re-
spiratory support weremissing for some patients (n = 291, or
18.3%), which may also have influenced the rates of respira-
tory support reported in this study.
The population in this study consisted mostly of men
(82%, which is higher than previously reported) and older
individuals.4,9,10 The median age of the patients admitted to
the ICUwas63 (IQR, 56-70) years old,which is the sameas the
medianageofall thepositive ItaliancaseswithCOVID-1912 sug-
gesting that, to date, older age alone is not a risk factor for ad-
mission to the ICU.
In this cohort of patients, 68% had at least 1 comorbidity,
in line with that reported by Wang et al (72.2%),9 but much
higher than in other reports.4,5 Similar to other previous
reports,4,9 hypertension was themost common comorbidity,
followed by cardiovascular disorders, hypercholesterolemia,
anddiabetes. Amongolder patients, comorbiditieswere com-
mon but a relatively small percentage of patients had pulmo-
nary disease.
Previous reportsdescribeddifferentmortality ratesamong
patients requiring ICU admission, from 16%9 to 38%,5 62%,10
67%,8 and 78%.11 In this study, at 5 weeks after the first ad-
mission in ICU, themajority of the patients (58%)were still in
the ICU, 16%of thepatientshadbeendischarged fromthe ICU,
and26%haddied in the ICU.Thedeath ratewashigher among
those who were older. However, these outcome data should
be interpreted with caution because most patients were still
hospitalized in the ICUandtheminimumfollow-upwas7days;
in particular, the mortality rate could eventually be higher.
To the best of our knowledge, this is the largest case se-
ries of patients with COVID-19 and severe illness who re-
quired admission to the ICU. Available data indicate consid-
erable variability among different countries in both the
proportion of severe cases of COVID-19 among those testing
positive and in the proportion of severe cases of COVID-19
among those hospitalized with the disease. Among western
countries, Italy seems to have a higher rate of severely ill pa-
tients and thus it is particularly relevant to report the demo-
graphic andclinical characteristics of thispopulationuponad-
mission to the ICU. Themajority of thepatients hadmoderate
to severe respiratory failure and required invasive mechani-
cal ventilation and high levels of PEEP.
These data could reflect a different organization of health
care systems in the world. In Italy, for instance, noninvasive
ventilation isdeliveredboth in ICUsandinotherhospitalwards.
The amount of intensive care support that has been provided
by intensivists outside of previously existing ICUs and newly
created ICUswasnotquantified.While the final figures arenot
yet available, the number of level 2 ICU beds (providing high-
flow oxygen, continuous positive airway pressure, or nonin-
vasive ventilation) is estimated to be high with a large num-
ber of beds created to increase capacity to deal with severely
ill patients during the COVID-19 outbreak. These data will be
collected soon to provide a complete description of the criti-
cally ill patients with COVID-19.
Thesedataalsosuggest that theneedfororgansupportand
intensive care, regardless of the reason, in the COVID-19 out-
break is substantial, with 9% of all positive cases being prob-
ably a conservative estimate. The volume of critically ill pa-
tientswith COVID-19 infection that ICUsmight be required to
managemaybe substantial, andadequate ICUcapacity todeal
with severe respiratory failure should be planned.
Limitations
This study has several limitations. First, this was a retrospec-
tive study, anddatawere acquired via telephone. Second, the
critical nature of the Lombardy situationdidnot allow the co-
ordinator to obtain more detailed information, such as base-
line medication use. Third, the follow-up time is still rela-
tively short comparedwith the course of the disease, and the
reportedmortalitydata and lengthof staydata reported in this
studycouldchange.Fourth, therewererelatively largeamounts
of missing data for some outcomes.
Conclusions
In this case series of critically ill patients with laboratory-
confirmedCOVID-19admittedtoICUsinLombardy,Italy,thema-
jority were oldermen, a large proportion requiredmechanical
ventilationandhigh levelsofPEEP,and ICUmortalitywas26%.
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